The impact of HFE mutations on haemoglobin and iron status in individuals experiencing repeated iron loss through blood donation
The impact of HFE mutations on haemoglobin and iron status in individuals experiencing repeated iron loss through blood donation
复制标题
DOI：
10.1111/j.1365-2141.2011.08952.x
复制
发表时间：
2012-02-01
影响因子：
6.5
通讯作者：
Busch, Michael P.
中科院分区：
文献类型：
--
作者：
Mast, Alan E.;Lee, Tzong-Hae;Busch, Michael P.
经常献血者会缺铁。HFE突变存在于超过30%的供体中。一项为期24个月的研究，888名首次/再激活的供体和1537名频繁供体测量血红蛋白和铁状态，以评估HFE突变如何影响缺铁性红细胞生成的发展。有两个HFE突变的捐赠者与有一个突变的捐赠者一样，增加了基线血红蛋白和铁储备，尽管程度较低。在多次献血中，HFE突变的献血者的血红蛋白和铁状态与那些缺乏突变的献血者相似。在高强度供体中，HFE突变的患病率没有增加。因此，在一般情况下，HFE突变不回火献血引起的血红蛋白和铁状态的变化。然而，在黑人供体中，基线时H63 D携带者增加，从首次/再激活供体的3.7%增加到频繁供体的15.8%，表明HFE突变对铁吸收的相对影响可能在种族/民族之间存在差异。在二次分析中，铁蛋白=12 μ g/l的供体静脉血红蛋白下降更慢;网织红细胞血红蛋白（CHr）=32.6 pg的供体血红蛋白恢复时间更短，表明这些生化指标比HFE突变状态更能反映供体对静脉切开术的反应。
Frequent blood donors become iron deficient. HFE mutations are present in over 30% of donors. A 24-month study of 888 first time/reactivated donors and 1537 frequent donors measured haemoglobin and iron status to assess how HFE mutations impact the development of iron deficiency erythropoiesis. Donors with two HFE mutations had increased baseline haemoglobin and iron stores as did those with one mutation, albeit to a lesser extent. Over multiple donations haemoglobin and iron status of donors with HFE mutations paralleled those lacking mutations. The prevalence of HFE mutations was not increased in higher intensity donors. Thus, in general, HFE mutations do not temper donation-induced changes in haemoglobin and iron status. However, in Black donors there was an increase of H63D carriers at baseline, from 3.7% in first time/reactivated donors to 15.8% in frequent donors, suggesting that the relative effects of HFE mutations on iron absorption may vary between racial/ethnic groups. In secondary analyses, venous haemoglobin decreased more slowly in donors with ferritin =12 mu g/l; and haemoglobin recovery time was shorter in donors with reticulocyte haemoglobin (CHr) =32.6 pg, indicating that these biochemical measures are better indicators of a donors response to phlebotomy than their HFE mutation status.